Prime-boost BCG vaccination with DNA vaccines based in β-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model

Vaccine

Volumn 31, Issue 4, 2013, Pages 676-684

  Cervantes Villagrana, Alberto R ^a,b   Hernández Pando, Rogelio ^c   Biragyn, Arya ^d   Castañeda Delgado, Julio ^a,b   Bodogai, Monica ^d   Martínez Fierro, Margarita ^e   Sada, Eduardo ^f   Trujillo, Valentin ^a   Enciso Moreno, Antonio ^a   Rivas Santiago, Bruno ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e UNIVERSIDAD AUTÓNOMA DE ZACATECAS   (Mexico)

^f Department of Research in Microbiology National Institute of Respiratory Disease ^*  (Mexico)

Author keywords

Ag85B; BCG; Defensins; DNA vaccine; ESAT6; Tuberculosis

Indexed keywords

AG85B ANTIGEN; BETA DEFENSIN 2; DNA VACCINE; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; MYCOBACTERIUM ANTIGEN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; TUBERCULOSIS CONTROL;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; BETA-DEFENSINS; DISEASE MODELS, ANIMAL; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; TH1 CELLS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINATION; VACCINES, DNA;

EID: 84871938556     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.042     Document Type: Article

References (46)

1. World Health Organization. Global tuberculosis control: WHO report 2011. Geneva: World Health Organization; 2011. viii, 246 pp.
2. Marquina-Castillo B., Garcia-Garcia L., Ponce-de-Leon A., Jimenez-Corona M.E., Bobadilla-Del V.M., Cano-Arellano B., et al. Virulence, immunopathology and transmissibility of selected strains of Mycobacterium tuberculosis in a murine model. Immunology 2009, 128(1):33-123. Epub 2009/02/05.
3. Mlambo C.K., Warren R.M., Poswa X., Victor T.C., Duse A.G., Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa. Int J Tuberc Lung Dis 2008, 12(1):99-104. Epub 2008/01/05.
4. Engstrom A., Morcillo N., Imperiale B., Hoffner S.E., Jureen P. Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates using pyrosequencing. J Clin Microbiol 2012, Epub 2012/03/31.
5. Brewer T.F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 2000, 31(Suppl. 3):S64-S67. Epub 2000/09/30.
6. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346(8986):45-1339. Epub 1995/11/18.
7. Aronson N.E., Santosham M., Comstock G.W., Howard R.S., Moulton L.H., Rhoades E.R., et al. Long-term efficacy of BCG vaccine in american indians and alaska natives: a 60-year follow-up study. JAMA 2004, 291(17):91-2086. Epub 2004/05/06.
8. Martino A., Sacchi A., Sanarico N., Spadaro F., Ramoni C., Ciaramella A., et al. Dendritic cells derived from BCG-infected precursors induce Th2-like immune response. J Leukoc Biol 2004, 76(4):34-827. Epub 2004/07/09.
9. Berredo-Pinho M., Kalume D.E., Correa P.R., Gomes L.H., Pereira M.P., da Silva R.F., et al. Proteomic profile of culture filtrate from the Brazilian vaccine strain Mycobacterium bovis BCG Moreau compared to M. bovis BCG Pasteur. BMC Microbiol 2011, 11:80. Epub 2011/04/22.
10. Hylkema M.N., Timens W., Luinge M., Van Der Werf N., Hoekstra M.O. The effect of bacillus Calmette-Guerin immunization depends on the genetic predisposition to Th2-type responsiveness. Am J Respir Cell Mol Biol 2002, 27(2):9-244. Epub 2002/08/02.
11. Sambandamurthy V.K., Jacobs W.R. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 2005, 7(5-6):61-955. Epub 2005/05/26.
12. Williams A., Hatch G.J., Clark S.O., Gooch K.E., Hatch K.A., Hall G.A., et al. Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. Tuberculosis (Edinb) 2005, 85(1-2):29-38. Epub 2005/02/03.
13. Hsu T., Hingley-Wilson S.M., Chen B., Chen M., Dai A.Z., Morin P.M., et al. The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci USA 2003, 100(21):5-12420. Epub 2003/10/15.
14. Hinchey J., Lee S., Jeon B.Y., Basaraba R.J., Venkataswamy M.M., Chen B., et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 2007, 117(8):88-2279. Epub 2007/08/03.
15. Pal P.G., Horwitz M.A. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect Immun 1992, 60(11):92-4781. Epub 1992/11/01.
16. Weinrich Olsen A., van Pinxteren L.A., Meng Okkels L., Birk Rasmussen P., Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 2001, 69(5):8-2773. Epub 2001/04/09.
17. Denis O., Tanghe A., Palfliet K., Jurion F., van den Berg T.P., Vanonckelen A., et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infect Immun 1998, 66(4):33-1527. Epub 1998/04/07.
18. Brun P., Zumbo A., Castagliuolo I., Delogu G., Manfrin F., Sali M., et al. Intranasal delivery of DNA encoding antigens of Mycobacterium tuberculosis by non-pathogenic invasive Escherichia coli. Vaccine 2008, 26(16):41-1934. Epub 2008/03/18.
19. Torres A.M., Kuchel P.W. The beta-defensin-fold family of polypeptides. Toxicon 2004, 44(6):8-581. Epub 2004/10/27.
20. Biragyn A., Ruffini P.A., Leifer C.A., Klyushnenkova E., Shakhov A., Chertov O., et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002, 298(5595):9-1025. Epub 2002/11/02.
21. Rivas-Santiago B., Cervantes-Villagrana A., Sada E., Hernandez-Pando R. Expression of Beta Defensin 2 in experimental pulmonary tuberculosis: tentative approach for vaccine development. Arch Med Res 2012, Epub 2012/06/19.
22. Biragyn A., Belyakov I.M., Chow Y.H., Dimitrov D.S., Berzofsky J.A., Kwak L.W. DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. Blood 2002, 100(4):9-1153. Epub 2002/08/01.
23. Biragyn A., Surenhu M., Yang D., Ruffini P.A., Haines B.A., Klyushnenkova E., et al. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J Immunol 2001, 167(11):53-6644. Epub 2001/11/21.
24. Mei H.F., Jin X.B., Zhu J.Y., Zeng A.H., Wu Q., Lu X.M., et al. beta-defensin 2 as an adjuvant promotes anti-melanoma immune responses and inhibits the growth of implanted murine melanoma in vivo. PLoS ONE 2012, 7(2):e31328. Epub 2012/02/22.
25. Delogu G., Fadda G. The quest for a new vaccine against tuberculosis. J Infect Dev Ctries 2009, 3(1):5-15. Epub 2009/09/15.
26. Berthet F.X., Rasmussen P.B., Rosenkrands I., Andersen P., Gicquel B. A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology 1998, 144(Pt 11):203-3195. Epub 1998/12/10.
27. Gordon S.V., Brosch R., Billault A., Garnier T., Eiglmeier K., Cole S.T. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol 1999, 32(3):55-643. Epub 1999/05/13.
28. Feng C.G., Palendira U., Demangel C., Spratt J.M., Malin A.S., Britton W.J. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis. Infect Immun 2001, 69(6):6-4174. Epub 2001/05/12.
29. Horwitz M.A., Harth G., Dillon B.J., Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000, 97(25):8-13853. Epub 2000/11/30.
30. Olsen A.W., Williams A., Okkels L.M., Hatch G., Andersen P. Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model. Infect Immun 2004, 72(10):50-6148. Epub 2004/09/24.
31. You Q., Wu Y., Jiang D., Wang C., Wei W., Yu X., et al. Immune responses induced by heterologous boosting of recombinant Bacillus Calmette-Guerin with Ag85B-ESAT6 fusion protein in levamisole-based adjuvant. Immunol Invest 2012, 41(4):28-412. Epub 2012/03/01.
32. van Soolingen D., Hermans P.W., de Haas P.E., Soll D.R., van Embden J.D. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991, 29(11):86-2578. Epub 1991/11/01.
33. Biragyn A., Tani K., Grimm M.C., Weeks S., Kwak L.W. Genetic fusion of chemokines to a self tumor antigen induces protective T-cell dependent antitumor immunity. Nat Biotechnol 1999, 17(3):8-253. Epub 1999/03/30.
34. Castillo-Rodal A.I., Castanon-Arreola M., Hernandez-Pando R., Calva J.J., Sada-Diaz E., Lopez-Vidal Y. Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis. Infect Immun 2006, 74(3):24-1718. Epub 2006/02/24.
35. Aguilar D., Infante E., Martin C., Gormley E., Gicquel B. Hernandez Pando R. Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain. Clin Exp Immunol 2007, 147(2):8-330. Epub 2007/01/17.
36. Lopez B., Aguilar D., Orozco H., Burger M., Espitia C., Ritacco V., et al. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin Exp Immunol 2003, 133(1):7-30. Epub 2003/06/26.
37. Wang Y.S., Wang G.Q., Wen Y.J., Wang L., Chen X.C., Chen P., et al. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1. Clin Cancer Res 2007, 13(22 Pt 1):87-6779. Epub 2007/11/17.
38. Olivares N., Leon A., Lopez Y., Puig A., Cadiz A., Falero G., et al. The effect of the administration of human gamma globulins in a model of BCG infection in mice. Tuberculosis (Edinb) 2006, 86(3-4):72-268. Epub 2006/05/09.
39. Medina E., Ryan L., LaCourse R., North R.J. Superior virulence of Mycobacterium bovis over Mycobacterium tuberculosis (Mtb) for Mtb-resistant and Mtb-susceptible mice is manifest as an ability to cause extrapulmonary disease. Tuberculosis (Edinb) 2006, 86(1):7-20. Epub 2005/10/29.
40. Woodworth J.S., Fortune S.M., Behar S.M. Bacterial protein secretion is required for priming of CD8+ T cells specific for the Mycobacterium tuberculosis antigen CFP10. Infect Immun 2008, 76(9):205-4199. Epub 2008/07/02.
41. Armitige L.Y., Jagannath C., Wanger A.R., Norris S.J. Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infect Immun 2000, 68(2):78-767. Epub 2000/01/20.
42. Rao V., Dhar N., Tyagi A.K. Modulation of host immune responses by overexpression of immunodominant antigens of Mycobacterium tuberculosis in bacille Calmette-Guerin. Scand J Immunol 2003, 58(4):61-449. Epub 2003/09/26.
43. Tala-Heikkila M.M., Tuominen J.E., Tala E.O. Bacillus Calmette-Guerin revaccination questionable with low tuberculosis incidence. Am J Respir Crit Care Med 1998, 157(4 Pt 1):7-1324. Epub 1998/05/01.
44. Buddle B.M., Wedlock D.N., Parlane N.A., Corner L.A., De Lisle G.W., Skinner M.A. Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination. Infect Immun 2003, 71(11):9-6411. Epub 2003/10/24.
45. Khader S.A., Bell G.K., Pearl J.E., Fountain J.J., Rangel-Moreno J., Cilley G.E., et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8(4):77-369. Epub 2007/03/14.
46. Agger E.M., Andersen P. A novel TB vaccine; towards a strategy based on our understanding of BCG failure. Vaccine 2002, 21(1-2):7-14. Epub 2002/11/22.